number
human
coronavirus
hcov
report
last
present
centuri
outbreak
eg
sar
mer
cov
caus
mortal
hundr
peopl
worldwid
problem
find
potent
drug
hcov
strain
lie
inabl
find
drug
stop
viral
replic
inhibit
import
protein
spite
limit
efficaci
potenti
side
effect
ribavirin
extens
use
first
choic
hcov
therefor
scientist
revert
toward
investig
differ
drug
specif
target
protein
studi
four
antihcv
drug
one
approv
fda
other
clinic
trial
test
hcov
polymeras
quantit
structureact
relationship
qsar
molecular
dock
use
compar
perform
select
nucleotid
inhibitor
parent
nucleotid
ribavirin
qsar
molecular
dock
show
superior
compar
ribavirin
mer
cov
result
also
report
hcv
show
perform
compar
ribavirin
strongli
suggest
vitro
studi
potenc
two
drug
mer
cov
dock
hcv
human
coronaviru
nucleotid
inhibitor
polymeras
qsar
number
human
coronavirus
hcov
report
last
present
centuri
outbreak
eg
sar
mer
cov
caus
mortal
hundr
peopl
worldwid
problem
find
potent
drug
hcov
strain
lie
inabl
find
drug
stop
viral
replic
inhibit
import
protein
spite
limit
efficaci
potenti
side
effect
ribavirin
extens
use
first
choic
hcov
therefor
scientist
revert
toward
investig
differ
drug
specif
target
protein
studi
four
antihcv
drug
one
approv
fda
other
clinic
trial
test
hcov
polymeras
quantit
structureact
relationship
qsar
molecular
dock
use
compar
perform
select
nucleotid
inhibitor
parent
nucleotid
ribavirin
qsar
molecular
dock
show
superior
compar
ribavirin
mer
cov
result
also
report
hcv
show
perform
compar
ribavirin
strongli
suggest
vitro
studi
potenc
two
drug
mer
cov
sar
fatal
rate
mer
fatal
rate
novemb
number
laboratori
confirm
infect
number
report
death
six
coronaviru
strain
report
zoonot
ie
transmiss
infect
anim
human
possibl
human
coronavirus
belong
alphacoronaviru
sar
mer
belong
betacoronaviru
first
four
strain
caus
mild
upper
respiratori
tract
infect
like
common
cold
sar
mer
caus
lower
respiratori
infect
bronchiti
bronchiol
pneumonia
report
sar
cov
mer
cov
host
bat
palm
civet
cat
dromedari
camel
respect
gener
coronavirus
envelop
positivesens
singlestrand
rna
kb
coronaviru
genom
translat
insid
host
cell
two
group
protein
structur
protein
spike
nucleocapsid
n
matrix
envelop
e
nonstructur
protein
rna
depend
rna
polymeras
helicas
coronavirus
enter
host
cell
either
endosom
nonendosom
pathway
polymeras
conserv
activ
site
aspart
take
part
nucleotidyl
transfer
differ
organ
virus
human
use
modifi
nucleotid
block
polymer
process
report
last
two
decad
first
fda
approv
nucleotid
inhibitor
sofosbuvir
decemb
sofosbuvir
approv
ribavirin
interferon
interferonfre
regimen
addit
also
approv
combin
target
protein
inhibitor
comput
aid
drug
design
cadd
util
comput
softwar
mimic
visual
character
behavior
biolog
molecul
often
use
molecular
model
conjunct
quantit
structureact
relationship
qsar
order
test
reactiv
ligand
bind
pattern
protein
activ
site
molecular
dock
usual
use
order
mimic
bind
ligand
protein
activ
site
use
score
function
neg
dock
score
mean
better
bind
drug
activ
site
target
protein
henc
inhibitori
perform
studi
combin
qsar
molecular
dock
util
evalu
bind
nucleotid
polymeras
inhibitor
sofosbuvir
hcov
polymeras
activ
site
drug
either
fda
approv
clinic
trial
studi
also
compar
bind
perform
nucleotid
inhibitor
nativ
nucleotid
ribavirin
studi
util
medicin
chemistri
platform
scigress
fujitsu
poland
instal
dell
precis
workstat
examin
molecular
dock
nucleotid
atp
utp
ctp
gtp
correspond
nucleotid
inhibitor
sofosbuvir
respect
ribavirin
differ
polymeras
hcov
strain
structur
nucleotid
nucleotid
inhibitor
first
sketch
use
scigress
tool
follow
geometri
optim
use
molecular
mechan
forc
field
method
structur
optim
use
semiempir
parameter
method
water
optim
structur
examin
calcul
infrar
ir
vibrat
spectra
use
method
order
ensur
real
neg
vibrat
final
structur
quantum
mechan
optim
accord
densiti
function
theori
dft
use
function
dzvp
basi
set
follow
calcul
ir
vibrat
spectra
level
stage
structur
final
optim
becom
readi
qsar
dock
calcul
similar
tabl
present
comparison
nucleotid
analogu
parent
nucleotid
drug
ribavirin
time
term
paramet
describ
structur
reactiv
instead
structur
stabil
tabl
reveal
nucleotid
analogu
reactiv
parent
nucleotid
bold
valu
tabl
brought
higher
better
valu
dipol
moment
tabl
recogn
higher
better
valu
dipol
moment
surfac
access
surfac
area
polariz
molar
refract
moreov
log
p
show
studi
compound
hydrophob
compar
parent
nucleotid
ribavirin
may
facilit
passag
membran
advantag
low
toxic
due
low
concentr
blood
emerg
natur
prodrug
convert
activ
form
insid
target
cell
report
hepat
c
viru
hcv
